Article Text

Download PDFPDF
The Authors' reply
  1. Dirk Roggenbuck1,
  2. Dirk Reinhold2,
  3. Thomas Wex3,
  4. Ulrike von Arnim3,
  5. Peter Malfertheiner3,
  6. Andreas Sturm4,
  7. Lael Werner4,
  8. Dimitrios P Bogdanos5,
  9. Martin W Laass6,
  10. Karsten Conrad7
  1. 1GA Generic Assays GmbH, Dahlewitz, Germany
  2. 2Institute of Molecular and Clinical Immunology, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
  3. 3Department of Gastroenterology, Hepatology and Infectious Diseases, Otto-von-Guericke-University Magdeburg, Magdeburg, Germany
  4. 4Department of Gastroenterology and Hepatology, Charité Universitätsmedizin Berlin, Berlin, Germany
  5. 5Division of Gene and Cell Based Therapy, King's College London School of Medicine at King's College Hospital, London, UK
  6. 6Children's Hospital, Technical University Dresden, Dresden, Germany
  7. 7Institute of Immunology, Technical University Dresden, Dresden, Germany
  1. Correspondence to Dr Karsten Conrad, Institute of Immunology, Technical University Dresden, Fetscherstraße 74, Dresden 01307, Germany; k_conrad{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

The Authors' reply We would like to thank Op De Beéck et al1 for their interest in the evaluation of antibodies to the zymogen granule membrane glycoprotein 2 (GP2) in patients with inflammatory bowel disease (IBD). Their meticulous investigation of a large, well-characterised cohort of patients and controls revealed good reproducibility, linearity and robustness of the anti-GP2 assays, confirming the assay performance reported in a recent study by our group.2 Both studies found a comparable, high specificity of anti-GP2 for Crohn's disease (CD). On testing 100 patients with ulcerative colitis (UC) and 162 blood donors (BDs) as controls in our study, the specificity reached a value of 94.3% (95% CI 90.7% to 96.8%). This value is similar to the specificity of 93.9% reported by Op De Beéck et al, including 118 UC …

View Full Text


  • Linked articles 233148.

  • Competing interests Dirk Roggenbuck is a shareholder of GA Generic Assays GmbH and Medipan GmbH. The remaining authors declare that they have no competing financial interests.

  • Patient consent Obtained.

  • Ethics approval This study was conducted with the approval of the Medical Faculty, University of Dresden.

  • Provenance and peer review Not commissioned; not externally peer reviewed.

Linked Articles